Skip to main content
HR 2747 107th Congress House Health Administrative procedure Bioethics Cloning Congress Congressional reporting requirements Cytology Department of Health and Human Services Drug therapy Economics and Public Finance Federal advisory bodies Federal aid to medical research Fetal tissues Genetic research Government Operations and Politics Human embryology Human genetics Immunosuppressive drugs Law Medical genetics

Stem Cell Research for Patient Benefit Act of 2001

Introduced: August 2, 2001 Introduced by: DeGette, Diana Democratic · Colorado See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 107th Congress ended
It never became law before the 107th Congress (2001–2002) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Aug 10, 2001
Referred to the Subcommittee on Health.
Aug 2, 2001
Referred to the House Committee on Energy and Commerce.
Aug 2, 2001
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service
Stem Cell Research for Patient Benefit Act 2001 - Requires the Director of the National Institutes of Health to: (1) conduct or support research using human pluripotent stem cells from embryos and fetal tissue in accordance with the National Institutes of Health Guidelines for Research Using Human Pluripotent Stem Cells; and (2) study and report to specified congressional committees on stem cells and the effectiveness of such guidelines.

Requires the Secretary of Health and Human Services to enter into an agreement with: (1) the Institute of Medicine under which the Institute shall assess the current state of knowledge about therapies, including somatic cell nuclear transfer and therapies using pharmaceuticals, that may be used to address immunological rejection of stem cells and differentiated cells and tissue derived from stem cells; and (2) another appropriate public or nonprofit private entity to conduct such assessment if the Institute declines.

Establishes the Biomedical Advisory Commission to study: (1) bioethical issues arising from research on human biology and applications of such research; and (2) emerging biomedical research, including the ethical, social, legal, and regulatory issues concerning such research and its clinical applications.

What's happening now August 10, 2001

Referred to the Subcommittee on Health.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
 Cosponsors 1
All 1 Democratic 1
D
McGovern, James P.
Massachusetts · Sep 6, 2001
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 2747: Stem Cell Research for Patient Benefit Act of 2001. 107th Congress. Open America. https://openamerica.io/bill/107-HR-2747/
MLA
"H.R. 2747: Stem Cell Research for Patient Benefit Act of 2001." 107th Congress, 2026, Open America, https://openamerica.io/bill/107-HR-2747/.
Bluebook (legal)
H.R. 2747, 107th Cong. (2026), https://openamerica.io/bill/107-HR-2747/.
Markdown link
[H.R. 2747: Stem Cell Research for Patient Benefit Act of 2001](https://openamerica.io/bill/107-HR-2747/)
Report a problem